SHANNON RYAN: Open Payments
NPI 1154602746 · CENTRAL POINT, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$505 in 29 payments from 11 companies in 2025. Trend: 2023 $603 · 2024 $717 · 2025 $505
Food & beverage: $505
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 15 | $191 |
| Alkermes, Inc. | 3 | $55 |
| Stryker Corporation | 1 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Neurocrine BioSciences, Inc. | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| ABBVIE INC. | 1 | $21 |
Products named: AUSTEDO XR, VARIAX, REXULTI, CAPLYTA, INGREZZA, FANAPT, LYBALVI, COBENFY.
Industry payments across OR — which companies pay providers there.
